Management of occupational and nonoccupational postexposure HIV prophylaxis

Current HIV/AIDS Reports

Volumn 1, Issue 4, 2004, Pages 159-165

  Katz, Mitchell H ^a   Gerberding, Julie Louise ^b  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b NONE

Author keywords

Human Immunodeficiency Virus; Human Immunodeficiency Virus Testing; Lamivudine; Receptive Anal Intercourse; Zidovudine

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

COUNSELING; DISEASE TRANSMISSION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEEDLESTICK INJURY; OCCUPATIONAL EXPOSURE; REVIEW; RISK ASSESSMENT; SEXUAL BEHAVIOR;

ANTI-HIV AGENTS; COUNSELING; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEEDLESTICK INJURIES; OCCUPATIONAL EXPOSURE; RISK ASSESSMENT; SEXUAL BEHAVIOR;

EID: 24144450368     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-004-0025-8     Document Type: Article

References (46)

1. Cardo DM, Culver DH, Ciesielski CA, et al.: A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997, 337:1485–1490. DOI: 10.1056/NEJM199711203372101
2. Updated U.S. Public Health Service: Guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Recomm Rep. 2001, 50(RR-11):1–52.
3. Henderson DK: Postexposure chemoprophylaxis for occupational exposures to the human immunodeficiency virus. JAMA 1999, 281:931–936. DOI: 10.1001/jama.281.10.931
4. Katz MH, Gerberding JL: Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use. N Engl J Med 1997, 336:1097–1100. DOI: 10.1056/NEJM199704103361512
5. Lurie P, Miller S, Hecht F, et al.: Postexposure prophylaxis after nonoccupational HIV exposure. JAMA 1998, 280:1769–1773. DOI: 10.1001/jama.280.20.1769
6. Laporte A, Jourdan N, Bouvet E, et al.: Post-exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians’ experiences and attitudes. AIDS 2002, 16:397–405. DOI: 10.1097/00002030-200202150-00011
7. Kinghorn GR, Evans B, Nunn A, et al.: Postexposure prophylaxis (PEP) after nonoccupational risk of HIV infection. Sex Transm Inf 1998, 74:304.
8. Gerberding JL: Prophylaxis for occupational exposure to HIV. Ann Intern Med 1996, 125:497–501.
9. DeGruttola V, Seage GR III, Mayer KH, Horsburgh CR Jr: Infectiousness of HIV between male homosexual partners. J Clin Epidemiol 1989, 42:849–856. DOI: 10.1016/0895-4356(89)90098-X
10. Wiley JA, Herschkorn SJ, Padian NS: Heterogeneity in the probability of HIV transmission per sexual contact: the case of male-to-female transmission in penile-vaginal intercourse. Stat Med 1989, 8:93–102. DOI: 10.1002/sim.4780080110
11. Downs AM, De Vincenzi I: Probability of heterosexual transmission of HIV: relationship to the number of unprotected sexual contacts. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:388–395.
12. Peterman TA, Stoneburner RL, Allen JR, et al.: Risk of human immunodeficiency virus transmission from heterosexual adults with transfusion-associated infections. JAMA 1988, 259:55–58. [Published erratum appears in JAMA 1989, 262:502.] DOI: 10.1001/jama.259.1.55
13. Vittinghoff E, Douglas J, Judson F, et al.: Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999, 150:306–311.
14. Kaplan EH, Heimer R: A model-based estimate of HIV in fectivity via needle sharing. J Acquir Immune Defic Syndr 1992, 5:1116–1118.
15. Royce R, Sena A, Cates WJ, Cohen M: Sexual transmission of HIV. N Engl J Med 1997, 336:1072–1078. DOI: 10.1056/NEJM199704103361507
16. Centers for Disease Control and Prevention: Notice to readers: approval of a new rapid test for HIV antibody. Morb Mortal Wkly Recomm Rep 2002, 51:1051–1052.
17. Holmberg SD: The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 1996, 86:642–654. DOI: 10.2105/AJPH.86.5.642
18. Bamberger JD, Waldo CR, Gerberding JL, Katz MH:Postexposure prophylaxis for human immunodeficiency virus (HIV) infection following sexual assault. Am J Med 1999, 106:323–326. Management of PEP after sexual assault. DOI: 10.1016/S0002-9343(99)00018-2
19. Wiebe ER, Comay SE, McGregor M, Ducceschi S: Offering HIV prophylaxis to people who have been sexually assaulted: 16 months’ experience in a sexual assault service. Can Med Assoc J 2000, 162:641–645.
20. Katz MH, Gerberding JL: Managing recent sexual exposures to HIV. Ann Intern Med 1998, 128:306–312. Comprehensive review of management of sexual exposure to HIV.
21. Tavares L, Roneker C, Johnston K, et al.: 3′-Azido-3′-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS. Cancer Res 1987, 47:3190–3194.
22. Mathes LE, Polas PJ, Hayes KA, et al.: Pre-and postexposure chemoprophylaxis: evidence that 3′-azido-3′-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response. Antimicrob Agents Chemother 1992, 36:2715–2721.
23. Ruprecht RM, O’Brien LG, Rossoni LD, Nusinoff-Lehrman S:Suppression of mouse viraemia and retroviral disease by 3′-azido-3′-deoxythymidine. Nature 1986, 323:467–469. DOI: 10.1038/323467a0
24. Connor EM, Sperling RS, Gelber R, et al.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994, 331:1173–1180. DOI: 10.1056/NEJM199411033311801
25. Wade NA, Birkhead GS, Warren BL, et al.: Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med 1998, 339:1409–1414. DOI: 10.1056/NEJM199811123392001
26. Jochimsen EM: Failures of zidovudine postexposure prophylaxis. Am J Med 1997, 102:52–55. DOI: 10.1016/S0002-9343(97)00062-4
27. Beltrami EM, Luo CC, de la Torre N, Cardo DM: Transmission of drug-resistant HIV after an occupational exposure despite postexposure prophylaxis with a combination drug regimen. Infect Control Hosp Epidemiol 2002, 23:345–348. DOI: 10.1086/502065
28. Kahn JO, Martin JN, Roland ME, et al.: Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP Study. J Infect Dis 2001, 183:707–714. Feasibility study of providing nonoccupational PEP; it demonstrated that it was feasible, adherence to treatment was high, and there were no long term side effects or seroconversions among the 401 participants. DOI: 10.1086/318829
29. Centers for Disease Control and Prevention: Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures — worldwide, 1997–2000. MMWR Morb Mort Wkly Rep 2001, 49:1153–1156.
30. Parkin JM, Murphy M, Anderson J, et al.: Tolerability and sideeffects of post-exposure prophylaxis for HIV infection. Lancet 2000, 355:722–723. DOI: 10.1016/S0140-6736(99)05005-9
31. Havens PL and American Academy of Pediatrics Committee on Pediatric AIDS: Postexposure prophylaxis in children and adolescents for nonoccupational exposure to human immunodeficiency virus. Pediatrics 2003, 111:1475–1489. DOI: 10.1542/peds.111.6.1475
32. Babl FE, Cooper ER, Damon B, et al.: HIV postexposure prophylaxis for children and adolescents. Am J Emerg Med 2000, 18:282–287. DOI: 10.1016/S0735-6757(00)90123-2
33. Gerberding JL: Occupational exposure to HIV in health care settings. N Engl J Med 2003, 348:826–833. DOI: 10.1056/NEJMcp020892
34. Salomon H, Wainberg MA, Brenner B, et al.: Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 2000, 14:F17-F23. DOI: 10.1097/00002030-200001280-00003
35. Brodine SK, Shaffer RA, Starkey MJ, et al.: Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999, 131:502–506.
36. Sulkowski MS, Ray SC, Thomas DL: Needlestick transmission of hepatitis C. JAMA 2002, 287:2406–2413. DOI: 10.1001/jama.287.18.2406
37. Kamal SM, Ismail A, Gram CS, et al.: Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004, 39:1721–1731. DOI: 10.1002/hep.20266
38. Nomura H, Sou S, Tanimoto H, et al.: Short-term interferonalfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004, 39:1213–1219. DOI: 10.1002/hep.20196
39. Wang SA, Panlilio AL, Doi PA, et al.: Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV postexposure prophylaxis registry. Infect Control Hosp Epidemio 2000, 21:780–785. DOI: 10.1086/501736
40. Tokars JI, Marcus R, Culver DH, et al.: Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood. Ann Intern Med 1993, 118:913–919.
41. Ippolito G, Puro V: Zidovudine toxicity in uninfected healthcare workers. Italian Registry of Antiretroviral Prophylaxis. Am J Med 1997, 102:58–62. DOI: 10.1016/S0002-9343(97)00064-8
42. Tannebaum J, Anastasoff J: The role of psychosocial assessment and support in occupational exposure management. AIDS Educ Prev 1997, 9:275–284.
43. Roland ME, Martin JN, Grant RM, et al.: Postexposure prophylaxis for human immunodeficiency virus infection after sexual or injection drug use exposure: identification and characterization of the source of exposure. J Infect Dis 2001, 184:1608–1612. DOI: 10.1086/324580
44. Praca Onze Study Team: Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr 2004, 35:519–525. DOI: 10.1097/00126334-200404150-00010
45. Desmond NM, Coker RJ: Should preventive antiretroviral treatment be offered following sexual exposure to HIV? The case for. Sex Transm Inf 1998, 74:144–145.
46. Evans B, Darbyshire J, Cartledge J: Should preventive antiretroviral treatment be offered following sexual exposure to HIV? Not yet! Sex Transm Infect 1998, 74:146–148.